---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-048158"
form_type: "8-K"
ticker: "BAX"
cik: "0000010456"
company_name: "BAXTER INTERNATIONAL INC"
filed_at: "2026-07-14T20:15:49+00:00"
generated_at: "2026-07-14T20:17:07.925274+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Baxter changes reportable segments to two: MPT and HST, effective Q2 2026

## Summary
- Former Pharmaceuticals segment moved into Infusion Therapies & Platforms division of MPT.
- Certain manufacturing facility sales previously in Other now reported in ITP division.
- Corporate cost allocation updated: some shared expenses now remain unallocated.
- Recast historical segment data for 2024, 2025, and Q1 2026 provided in Exhibit 99.1.
- No impact on consolidated net income, EPS, total assets, or stockholders' equity.

## SEC filing metadata
- accession: 0001628280-26-048158
- form_type: 8-K
- ticker: BAX
- cik: 0000010456
- company_name: BAXTER INTERNATIONAL INC
- filed_at: 2026-07-14T20:15:49+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/10456/000162828026048158/0001628280-26-048158-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/10456/000162828026048158/bax-20260714.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-048158
- JSON: https://secwatch.observer/filing/0001628280-26-048158.json
- Plain text: https://secwatch.observer/filing/0001628280-26-048158.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.